secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021181
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q1 net product revenue $71.4M; net income $1.6M vs $47.8M loss YoY
-------------------------------------------------------------------------

- Net product revenue $71.4M from RELYVRIO/ALBRIOZA ALS sales; cost of sales $5.3M.
- Net income $1.6M ($0.02/share) vs net loss $47.8M ($0.93/share) in Q1 2022.
- Cash and investments $345.7M at March 31, 2023, down slightly from $346.9M at Dec 31, 2022.
- Phase 3 PHOENIX ALS trial fully enrolled (664 participants); topline results expected mid-2024.
- Plans to initiate global Phase 3 trial of AMX0035 in progressive supranuclear palsy in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/0000950170-23-021181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023021181/amlx-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer